Serum Thyrotropin Concentrations are not Predictive of Aggressive Breast Cancer Biology in Euthyroid Individuals |
| |
| Institution: | 1. From the UCLA David Geffen School of Medicine, Los Angeles, California.;2. Department of Biomathematics; UCLA David Geffen School of Medicine, Los Angeles, California.;3. Section of Endocrine Surgery; UCLA David Geffen School of Medicine, Los Angeles, California.;4. Division of Hematology/Oncology; UCLA David Geffen School of Medicine, Los Angeles, California.;5. Department of Pathology and Laboratory Medicine; UCLA David Geffen School of Medicine, Los Angeles, California.;6. Division of Endocrinology; VA Greater Los Angeles Healthcare System, Los Angeles, California.;7. Division of Endocrinology, Diabetes, and Hypertension; UCLA David Geffen School of Medicine, Los Angeles, California.;1. From the Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas;2. Division of Pediatric Endocrinology, Department of Pediatrics, University of Alabama School of Medicine, Birmingham, Alabama;3. Department of Epidemiology in the School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama;4. Division of Pediatric Surgery, Department of Surgery, University of Alabama School of Medicine, Birmingham, Alabama;5. School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.;1. From the Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland;2. Department of Oncological Gastroenterology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland;3. Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland;4. Department of Medical Genetics, Centre for Biostructure, Medical University of Warsaw, Warsaw, Poland. |
| |
| Abstract: | Objective: The potential influence of hypothyroidism on breast cancer remains incompletely understood. The objective of this study was to investigate the relationship between serum thyrotropin (thyroid-stimulating hormone, TSH) concentration and markers of aggressive breast cancer biology as defined by receptor expression profile, tumor grade, and American Joint Committee on Cancer (AJCC) stage characteristics.Methods: This was a retrospective cohort study of patients from 2002 to 2014. All breast cancer patients who had complete receptor (estrogen receptor, ER; progesterone receptor, PR; and human epidermal growth factor receptor 2, Her2/neu) and prediagnosis serum TSH data (n = 437) were included. All patients had 1 of 6 receptor profiles: ER+ PR+ Her2/neu-, ER+ PR- Her2/neu-, ER+ PR+ Her2/neu+, ER+ PR- Her2/neu+, ER- PR- Her2/neu+, or ER- PR- Her2/neu-. Log-transformed serum TSH concentrations were analyzed using multinomial and logistic regressions to identify potential relationships with markers of breast cancer aggressiveness.Results: Increasing serum TSH concentration was associated with a lower probability of having the receptor expression profile ER+ PR+ Her2/neu+ compared to patients with the ER+ PR+ Her2/neu- profile (odds ratio OR] = 0.52, P = .0045). No significant associations between other receptor expression profiles and serum TSH concentration were found. All time-weighted and unweighted median serum TSH concentrations were within normal limits. No significant associations between serum TSH concentration and tumor grade, overall AJCC stage, tumor size (T), lymph node positivity (N), or presence of metastasis (M) were observed.Conclusions: Serum TSH was not associated with markers of breast cancer aggressiveness in our cohort.Abbreviations: AJCC = American Joint Committee on Cancer ER = estrogen receptor Her2/neu = human epidermal growth factor receptor 2 M = metastasis N = lymph node positivity OR = odds ratio PR = progesterone receptor T = tumor size TSH = thyroid stimulating hormone UCLA = University of California Los Angeles |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
